Regeneron

Results: 62



#Item
1  Regeneron Spotlight Jonathan Cruz, Postdoctoral Fellow Jon received his BS from Rutgers University in 2007 in Food Science and Microbiology. During his time as an undergraduate he studied how antimicrobial

  Regeneron Spotlight Jonathan Cruz, Postdoctoral Fellow Jon received his BS from Rutgers University in 2007 in Food Science and Microbiology. During his time as an undergraduate he studied how antimicrobial

Add to Reading List

Source URL: rubest.rutgers.edu

Language: English - Date: 2017-10-08 17:18:10
    2CONNECTED FUTURE INNOVATION CHALLENGE COMPETITION OFFICIAL RULES PLEASE REVIEW THESE OFFICIAL RULES BEFORE ENTERING THE COMPETITION. ENTRY INTO THE COMPETITION IS FREE AND NO PAYMENT OR PURCHASE IS NECESSARY TO ENTER OR

    CONNECTED FUTURE INNOVATION CHALLENGE COMPETITION OFFICIAL RULES PLEASE REVIEW THESE OFFICIAL RULES BEFORE ENTERING THE COMPETITION. ENTRY INTO THE COMPETITION IS FREE AND NO PAYMENT OR PURCHASE IS NECESSARY TO ENTER OR

    Add to Reading List

    Source URL: www.autodeskcompetitions.com

    Language: English - Date: 2015-08-28 12:40:51
    3Finley_MSM Consortium Meeting_2013.key

    Finley_MSM Consortium Meeting_2013.key

    Add to Reading List

    Source URL: www.cse-lab.ethz.ch

    Language: English - Date: 2015-10-12 08:25:52
    4Project Tomorrow® is pleased to announce the 2016 Innovation in Education Awards The Project Tomorrow Innovation in Education Awards recognizes schools, educational leaders, and students for their innovative uses of sci

    Project Tomorrow® is pleased to announce the 2016 Innovation in Education Awards The Project Tomorrow Innovation in Education Awards recognizes schools, educational leaders, and students for their innovative uses of sci

    Add to Reading List

    Source URL: www.tomorrow.org

    Language: English - Date: 2016-04-05 14:44:13
    5October 8, 2015 Regeneron and Sanofi Announce Publication of Positive Phase 2b Dupilumab Data in The Lancet Study Evaluated Adult Patients with Moderate-to-Severe Atopic Dermatitis who were Inadequately Controlled by To

    October 8, 2015 Regeneron and Sanofi Announce Publication of Positive Phase 2b Dupilumab Data in The Lancet Study Evaluated Adult Patients with Moderate-to-Severe Atopic Dermatitis who were Inadequately Controlled by To

    Add to Reading List

    Source URL: files.shareholder.com

    Language: English
      6October 1, 2015 Regeneron Announces Collaboration with Mitsubishi Tanabe Pharma for Investigational Pain Therapy Fasinumab in Asia NGF Antibody Fasinumab Currently in Phase 2/3 Osteoarthritis Trial Tarrytown, N.Y., Oct.

      October 1, 2015 Regeneron Announces Collaboration with Mitsubishi Tanabe Pharma for Investigational Pain Therapy Fasinumab in Asia NGF Antibody Fasinumab Currently in Phase 2/3 Osteoarthritis Trial Tarrytown, N.Y., Oct.

      Add to Reading List

      Source URL: files.shareholder.com

      Language: English
        7Dow Jones VentureWire Versant-Backed Inception Sciences Creates Eye-Drug Startup With Bayer Healthcare th November

        Dow Jones VentureWire Versant-Backed Inception Sciences Creates Eye-Drug Startup With Bayer Healthcare th November

        Add to Reading List

        Source URL: www.versantventures.com

        Language: English - Date: 2014-01-21 19:48:19
        8Project Summary Benefit-Cost Evaluation1 Regeneron Pharmaceuticals, Inc. Initial Jobs: 565 Retained Jobs: 565 over 3 years

        Project Summary Benefit-Cost Evaluation1 Regeneron Pharmaceuticals, Inc. Initial Jobs: 565 Retained Jobs: 565 over 3 years

        Add to Reading List

        Source URL: www.esd.ny.gov

        Language: English - Date: 2011-08-17 16:07:29
          9July 8, 2015 Regeneron and Sanofi Announce Phase 3 Results Showing LDL-C Reductions of More Than 60 Percent in Japanese Patients Treated with Praluent® (alirocumab) Injection Primary results from ongoing 52 week ODYSSE

          July 8, 2015 Regeneron and Sanofi Announce Phase 3 Results Showing LDL-C Reductions of More Than 60 Percent in Japanese Patients Treated with Praluent® (alirocumab) Injection Primary results from ongoing 52 week ODYSSE

          Add to Reading List

          Source URL: files.shareholder.com

          Language: English
            10World’s Leading Genomic Research Center at Regeneron Accelerates Life Science Research with AMAX Powerful HPC Solution The Problem To blend highly efficient, rapid sequencing technology with the research and clinical e

            World’s Leading Genomic Research Center at Regeneron Accelerates Life Science Research with AMAX Powerful HPC Solution The Problem To blend highly efficient, rapid sequencing technology with the research and clinical e

            Add to Reading List

            Source URL: www.amax.com

            Language: English - Date: 2011-06-15 20:17:00